Drugs / ISL/ULO
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07266831 | Dec 2025 → Mar 2029 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISL/ULO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266831 ↗ |
| Route | Oral | “ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks” NCT07266831 ↗ |